3D Bioprinting Market Report
RA01799
3D Bioprinting Market by Technology (Magnetic Levitation, Syringe-based, Inkjet-based, Laser-based, and Others), Application (Medical, Bioinks, Dental, Biosensors, Consumer/Personal Product Testing, and Food & Animal Product), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032
3D Bioprinting Overview
A manufacturing technique known as three-dimensional printing (or 3D printing) uses layers of material to create tangible objects. Although 3D bioprinting was intended to produce functioning organs from biological materials, the technology is not yet developed enough to do so. This technology is the combination of biotechnology and three-dimensional printing which produces living tissue and organs. To guarantee cell survival and the correct mechanical qualities for tissue creation, the bioinks are carefully prepared.
The availability of suitable biomaterials that can support cell growth and necessary mechanical properties are the factors on which success of 3D bioprinting depends. Hydrogels, bioinks, and biodegradable polymers, among other materials, are being developed and enhanced for use in bioprinting. To improve cell behavior and tissue regeneration, researchers are also investigating the insertion of bioactive chemicals and signaling elements.
Global 3D Bioprinting Market Analysis
The global 3D bioprinting market size was $1,329.9 million in 2022 and is predicted to grow with a CAGR of 12.3%, by generating a revenue of $4,200.0 million by 2032.
COVID-19 Impact on Global 3D Bioprinting Market
The pandemic brought to light the value of biomedical research and cutting-edge medical technology. As researchers investigated its potential for uses in personalized medicine, drug discovery, and tissue engineering, the 3D bioprinting market received more funding and attention. The interest in 3D bioprinting has been sparked by the need for creative solutions to healthcare issues like organ shortages and drug testing. It became critical to have trustworthy and physiologically accurate tissue models available for studying COVID-19 and creating potential cures and vaccinations. In order to study the disease's processes and test potential treatments, 3D bioprinting helped to speed up the creation of tissue models that closely resemble human organs infected by the virus.
The COVID-19 pandemic brought attention to the value of cutting-edge medical technology. Specialized capabilities in tissue engineering, regenerative medicine, and drug discovery are provided by 3D bioprinting. The need for 3D bioprinting technologies is anticipated to increase as the healthcare sector places more emphasis on individualized treatment and patient-specific medications. New biomaterials that closely resemble human tissues and organs are constantly being explored and developed by researchers and business professionals. This can increase the biocompatibility, mechanical characteristics, and cell survival of 3D-printed constructions, improving their quality and functioning.
Advancements in Tissue Engineering to Drive the Market Growth
Tissue engineering, which entails the creation of functional human tissues and organs, dominates the 3D bioprinting business. 3D bioprinting permits the creation of complicated, three-dimensional structures that closely resemble genuine tissues by meticulously arranging cells, biomaterials, and bioinks.. Organ donors are in short supply compared to the need for transplants. The creation of functional organs including kidneys, livers, and hearts is possible using a patient's own cells or similar materials and 3D bioprinting. Owing to this technology, the field of organ transplantation may see a revolution that could reduce the duration of the organ transplant waiting list.
Global healthcare challenges include chronic diseases such organ failure, diabetes, and cardiovascular disease. For the development of illness models, individualized medication testing, and regenerative medicines to treat various disorders, 3D bioprinting is always helpful The 3D bioprinting industry is primarily driven by the capacity to produce patient-specific tissues and organs for the research of diseases and the development of focused treatments.
Regulatory Challenges to Restrain Market Growth
Since 3D bioprinting is a relatively new part, standards and regulatory frameworks are still developing. For 3D bioprinted items, especially those intended for clinical use, obtaining regulatory approval can be challenging and time-consuming. The requirement to abide by current legal restrictions on efficacy, safety, and morality restricts the market growth. A significant obstacle to their broad adoption is the expensive cost of 3D bioprinting equipment and supplies. Costs associated with maintenance and operation can be high for high-quality bioprinters, bioinks, and biomaterials. Due of the high cost, it is challenging for smaller research institutions and companies to invest in 3D bioprinting technology. In order to fulfil demand, 3D bioprinted tissues and organs production must be scaled up. Although complex structures can be precisely manufactured with 3D bioprinting, the production volumes are currently constrained. For wider applications, a barrier that needs to be removed is the requirement to affordably create larger and more complex tissue structures.
Ongoing R&D Activities to Drive Excellent Opportunities
3D bioprinting offers the capacity to create complex and functional tissues and organs in order to address the rising demand for organ transplantation. The ability to produce patient-specific tissues and organs will allow for personalized therapy and reduce the possibility of rejection, which offers great potential for regenerative medicine. For drug testing and development, 3D bioprinted tissues can provide more precise and physiologically appropriate models. 3D bioprinted constructions can offer more precise forecasts of medication efficacy, toxicity, and safety profiles by simulating the milieu of human tissues. This might reduce the need for animal testing and speed the development of novel medications.
To study illness causes, test novel medicines, and develop personalized treatment procedures, researchers can generate disease models using 3D bioprinting that closely resemble real tissues. The use of patient-specific cells in 3D bioprinting can help advance personalized medicine, which makes treatments to each patient based on their particular needs and genetic profiles.
Global 3D Bioprinting Market Share, by Technology, 2022
The inkjet-based sub-segment accounted for the highest share in 2022. Inkjet-based bioprinting allows for the precise and fine-tuned deposition of bioinks, enabling the construction of intricate and sophisticated structures at the microscale level. With the help of this technique, tissues and organs with improved structural and functional qualities can be created by precisely controlling the positioning and arrangement of cells and biomaterials. A variety of bioink formulations, including hydrogels, cell suspensions, and biomaterial-based inks, are compatible with inkjet-based bioprinting. Due to their adaptability, researchers and bioprinting businesses can investigate a wide range of materials and fine-tune bioink compositions for particular tissue engineering applications. In addition, inkjet-based bioprinting makes possible to incorporate several cell types and growth factors, increasing the complexity and functioning of the printed constructions. High-throughput production can be easily accommodated by scaling up inkjet-based bioprinting. The bioprinting technique is more effective and productive since it can print numerous constructions at once due to the quick deposit of bioink droplets. This scalability is crucial for the production of vast quantities of tissue and the commercialization of bioprinted goods.
Global 3D Bioprinting Market Share, by Application, 2022
The medical sub-segment accounted for the highest market size in 2022. The scarcity of organs for transplantation may be resolved through 3D bioprinting. Researchers can bioprint functioning tissues and organs that closely mimic human tissues using patient-specific cells and bioinks. With the development of patient-specific organs, less reliance on immunosuppressive medications, and increased transplant success rates, this technique shows enormous promise. In addition to disease modelling, toxicity testing, and medication screening, 3D bioprinted models are utilized, which improves the efficiency and lowers the cost of the process of generating new pharmaceuticals. This may reduce the need for animal testing while increasing the precision of preclinical drug testing.
The creation of specialized medical implants and prosthetics catered to the demands of specific patients is made possible by 3D bioprinting. Bioprinters may produce implants and prosthetics that precisely match each patient's individual anatomy by scanning and modelling the patient's anatomical data, improving comfort, functionality, and patient outcomes. The capacity to create complex and useful tissues and organs via 3D bioprinting enables medical professionals to fulfil the growing demand for organ transplantation and the lack of organ donors. There is a lot of potential for regenerative medicine in the production of patient-specific tissues and organs since it will allow for individualized therapy and reduce the possibility of rejection. Bioprinted constructs can aid in the regeneration of diseased or damaged tissues by integrating growth factors and cells into structures that imitate the extracellular matrix. Applications for this technology include cartilage repair, bone regeneration, and skin grafts.
Global 3D Bioprinting Market Share, by Region, 2022
The Asia-Pacific 3D bioprinting market accounted for the highest share in 2022. The demand for personalized medicine and specialized healthcare solutions is driven by the region's huge and diversified population. The ability to produce tissues and organs that are unique to a patient through 3D bioprinting is in line with the region's emphasis on precision medicine and individualized healthcare. The region's ability to manage specific genetic and racial variations in tissue engineering and transplantation is a crucial component in 3D bioprinting's adoption in the region. Countries in Asia-Pacific are investing highly in the healthcare facilities and services. Also the countries are taking initiative in building tissue engineering research facilities, bioprinting labs and regenerative medicine centers. These investments foster cooperation between research institutions, hospitals, and industry actors while creating a favorable climate for the expansion of the 3D bioprinting sector. In order to improve the field of 3D bioprinting, academic institutions, healthcare providers, and industrial participants have worked together throughout Asia-Pacific. These partnerships boost 3D bioprinting technology commercialization, research acceleration, and knowledge sharing. Such alliances are essential to the expansion of the market in the region.
Competitive Scenario in the Global 3D Bioprinting Market
Product development and geographic expansion are major strategies adopted by the key players functioning in the highly competitive global 3D bioprinting market. For instance, in November 2019, CELLINK created the most sophisticated 3D bioprinting tool, Bio X6, as well as Lumen X, which creates vascular structures. In addition, the Swedish business Fluicell introduced Biopixlar, a high-resolution bioprinting technology available in both 3D and 2D formats.
Some of the leading 3D bioprinting market players are EnvisionTEC, Inc., Organovo Holdings, Inc., Inventia Life Science PTY LTD, Vivax Bio, LLC, Poietis, Allevi, Cellink Global, Cyfuse Biomedical K.K., and Regemat 3D S.L.
| Aspect | Particulars |
| Historical Market Estimations | 2021 |
| Base Year for Market Estimation | 2022 |
| Forecast Timeline for Market Projection | 2023-2032 |
| Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
| Segmentation by Technology |
|
| Segmentation by Application |
|
| Key Companies Profiled |
|
Q1. What is the size of the 3D bioprinting market?
A. The size of the 3D bioprinting market was over $1,329.9 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 12.3% during the forecast period.
Q2. Which are the major companies in the 3D bioprinting market?
A. Inventia Life Science PTY LTD and Cyfuse Biomedical K.K. are some of the key players in the global 3D bioprinting market.
Q3. Which region, among others, possesses greater investment opportunities in the future?
A. Asia-Pacific possesses great investment opportunities for investors in the future.
Q4. What are the strategies opted by the leading players in this market?
A. Product development and geographic expansion are the two key strategies opted by the operating companies in this market.
Q5. Which companies are investing more on R&D practices?
A. Inventia Life Science PTY LTD and Cyfuse Biomedical K.K. are the companies investing more on R&D activities for developing new products and technologies.
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global 3D Bioprinting Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on 3D Bioprinting Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. 3D Bioprinting Market, By Technology
5.1. Overview
5.2 Research Applications
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 Clinical Application
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 Research Dive Exclusive Insights
5.4.1 Market attractiveness
5.4.2 Competition heatmap
-
6. 3D Bioprinting Market, By Distribution Channel
6.1. Overview
6.2 Research Organization & Academic Institutes
6.2.1 Definition, key trends, growth factors, and opportunities
6.2.2 Market size analysis, by region, 2020-2027
6.2.3 Market share analysis, by country, 2020-2027
6.3 Biopharmaceuticals Companies
6.3.1 Definition, key trends, growth factors, and opportunities
6.3.2 Market size analysis, by region, 2020-2027
6.3.3 Market share analysis, by country, 2020-2027
6.4 Hospital
6.4.1 Definition, key trends, growth factors, and opportunities
6.4.2 Market size analysis, by region, 2020-2027
6.4.3 Market share analysis, by country, 2020-2027
6.5 Research Dive Exclusive Insights
6.5.1 Market attractiveness
6.5.2 Competition heatmap
-
7. 3D Bioprinting Market, By Cause
7.1. Overview
7.2 Living Cells
7.2.1 Definition, key trends, growth factors, and opportunities
7.2.2 Market size analysis, by region, 2020-2027
7.2.3 Market share analysis, by country, 2020-2027
7.3 Hydrogels
7.3.1 Definition, key trends, growth factors, and opportunities
7.3.2 Market size analysis, by region, 2020-2027
7.3.3 Market share analysis, by country, 2020-2027
7.4 Extracellular Matrices
7.4.1 Definition, key trends, growth factors, and opportunities
7.4.2 Market size analysis, by region, 2020-2027
7.4.3 Market share analysis, by country, 2020-2027
7.5 Other Biomaterial
7.5.1 Definition, key trends, growth factors, and opportunities
7.5.2 Market size analysis, by region, 2020-2027
7.5.3 Market share analysis, by country, 2020-2027
7.6 Research Dive Exclusive Insights
7.6.1 Market attractiveness
7.6.2 Competition heatmap
-
8. 3D Bioprinting Market, By Filling
8.1. Overview
8.2 3D Bioprinters
8.2.1 Definition, key trends, growth factors, and opportunities
8.2.2 Market size analysis, by region, 2020-2027
8.2.3 Market share analysis, by country, 2020-2027
8.3 Bioinks
8.3.1 Definition, key trends, growth factors, and opportunities
8.3.2 Market size analysis, by region, 2020-2027
8.3.3 Market share analysis, by country, 2020-2027
8.4 Research Dive Exclusive Insights
8.4.1 Market attractiveness
8.4.2 Competition heatmap
9. 3D Bioprinting Market, By Region
9.1 North America
9.1.1 U.S
9.1.1.1 Market size analysis, By Technology, 2020-2027
9.1.1.2 Market size analysis, By Distribution Channel, 2020-2027
9.1.1.3 Market size analysis, By Cause, 2020-2027
9.1.1.4 Market size analysis, By Filling, 2020-2027
9.1.2 Canada
9.1.2.1 Market size analysis, By Technology, 2020-2027
9.1.2.2 Market size analysis, By Distribution Channel, 2020-2027
9.1.2.3 Market size analysis, By Cause, 2020-2027
9.1.2.4 Market size analysis, By Filling, 2020-2027
9.1.3 Mexico
9.1.3.1 Market size analysis, By Technology, 2020-2027
9.1.3.2 Market size analysis, By Distribution Channel, 2020-2027
9.1.3.3 Market size analysis, By Cause, 2020-2027
9.1.3.4 Market size analysis, By Filling, 2020-2027
9.1.4 Research Dive Exclusive Insights
9.1.4.1 Market attractiveness
9.1.4.2 Competition heatmap
9.2 Europe
9.2.1 Germany
9.2.1.1 Market size analysis, By Technology, 2020-2027
9.2.1.2 Market size analysis, By Distribution Channel, 2020-2027
9.2.1.3 Market size analysis, By Cause, 2020-2027
9.2.1.4 Market size analysis, By Filling, 2020-2027
9.2.2 UK
9.2.2.1 Market size analysis, By Technology, 2020-2027
9.2.2.2 Market size analysis, By Distribution Channel, 2020-2027
9.2.2.3 Market size analysis, By Cause, 2020-2027
9.2.2.4 Market size analysis, By Filling, 2020-2027
9.2.3 France
9.2.3.1 Market size analysis, By Technology, 2020-2027
9.2.3.2 Market size analysis, By Distribution Channel, 2020-2027
9.2.3.3 Market size analysis, By Cause, 2020-2027
9.2.3.4 Market size analysis, By Filling, 2020-2027
9.2.4 Spain
9.2.4.1 Market size analysis, By Technology, 2020-2027
9.2.4.2 Market size analysis, By Distribution Channel, 2020-2027
9.2.4.3 Market size analysis, By Cause, 2020-2027
9.2.4.4 Market size analysis, By Filling, 2020-2027
9.2.5 Italy
9.2.5.1 Market size analysis, By Technology, 2020-2027
9.2.5.2 Market size analysis, By Distribution Channel, 2020-2027
9.2.5.3 Market size analysis, By Cause, 2020-2027
9.2.5.4 Market size analysis, By Filling, 2020-2027
9.2.6 Rest of Europe
9.2.6.1 Market size analysis, By Technology, 2020-2027
9.2.6.2 Market size analysis, By Distribution Channel, 2020-2027
9.2.6.3 Market size analysis, By Cause, 2020-2027
9.2.6.4 Market size analysis, By Filling, 2020-2027
9.2.7 Research Dive Exclusive Insights
9.2.7.1 Market attractiveness
9.2.7.2 Competition heatmap
9.3 Asia-Pacific
9.3.1 China
9.3.1.1 Market size analysis, By Technology, 2020-2027
9.3.1.2 Market size analysis, By Distribution Channel, 2020-2027
9.3.1.3 Market size analysis, By Cause, 2020-2027
9.3.1.4 Market size analysis, By Filling, 2020-2027
9.3.2 Japan
9.3.2.1 Market size analysis, By Technology, 2020-2027
9.3.2.2 Market size analysis, By Distribution Channel, 2020-2027
9.3.2.3 Market size analysis, By Cause, 2020-2027
9.3.2.4 Market size analysis, By Filling, 2020-2027
9.3.3 India
9.3.3.1 Market size analysis, By Technology, 2020-2027
9.3.3.2 Market size analysis, By Distribution Channel, 2020-2027
9.3.3.3 Market size analysis, By Cause, 2020-2027
9.3.3.4 Market size analysis, By Filling, 2020-2027
9.3.4 Australia
9.3.4.1 Market size analysis, By Technology, 2020-2027
9.3.4.2 Market size analysis, By Distribution Channel, 2020-2027
9.3.4.3 Market size analysis, By Cause, 2020-2027
9.3.4.4 Market size analysis, By Filling, 2020-2027
9.3.5 South Korea
9.3.5.1 Market size analysis, By Technology, 2020-2027
9.3.5.2 Market size analysis, By Distribution Channel, 2020-2027
9.3.5.3 Market size analysis, By Cause, 2020-2027
9.3.5.4 Market size analysis, By Filling, 2020-2027
9.3.6 Rest of Asia-Pacific
9.3.6.1 Market size analysis, By Technology, 2020-2027
9.3.6.2 Market size analysis, By Distribution Channel, 2020-2027
9.3.6.3 Market size analysis, By Cause, 2020-2027
9.3.6.4 Market size analysis, By Filling, 2020-2027
9.3.7 Research Dive Exclusive Insights
9.3.7.1 Market attractiveness
9.3.7.2 Competition heatmap
9.4 LAMEA
9.4.1 Brazil
9.4.1.1 Market size analysis, By Technology, 2020-2027
9.4.1.2 Market size analysis, By Distribution Channel, 2020-2027
9.4.1.3 Market size analysis, By Cause, 2020-2027
9.4.1.4 Market size analysis, By Filling, 2020-2027
9.4.2 Saudi Arabia
9.4.2.1 Market size analysis, By Technology, 2020-2027
9.4.2.2 Market size analysis, By Distribution Channel, 2020-2027
9.4.2.3 Market size analysis, By Cause, 2020-2027
9.4.2.4 Market size analysis, By Filling, 2020-2027
9.4.3 UAE
9.4.3.1 Market size analysis, By Technology, 2020-2027
9.4.3.2 Market size analysis, By Distribution Channel, 2020-2027
9.4.3.3 Market size analysis, By Cause, 2020-2027
9.4.3.4 Market size analysis, By Filling, 2020-2027
9.4.4 South Africa
9.4.4.1 Market size analysis, By Technology, 2020-2027
9.4.4.2 Market size analysis, By Distribution Channel, 2020-2027
9.4.4.3 Market size analysis, By Cause, 2020-2027
9.4.4.4 Market size analysis, By Filling, 2020-2027
9.4.5 Rest of LAMEA
9.4.5.1 Market size analysis, By Technology, 2020-2027
9.4.5.2 Market size analysis, By Distribution Channel, 2020-2027
9.4.5.3 Market size analysis, By Cause, 2020-2027
9.4.5.4 Market size analysis, By Filling, 2020-2027
9.4.6 Research Dive Exclusive Insights
9.4.6.1 Market attractiveness
9.4.6.2 Competition heatmap
10. Competitive Landscape
10.1 Top winning strategies, 2020-2027
10.1.1 By strategy
10.1.2 By year
10.2 Strategic overview
10.3 Market share analysis, 2020-2027
11. Company Profiles
11.1 Organovo Holdings, Inc.
11.1.1 Overview
11.1.2 Business segments
11.1.3 Product portfolio
11.1.4 Financial performance
11.1.5 Recent developments
11.1.6 SWOT analysis
11.2 CELLINK
11.2.1 Overview
11.2.2 Business segments
11.2.3 Product portfolio
11.2.4 Financial performance
11.2.5 Recent developments
11.2.6 SWOT analysis
11.3 Allevi Inc.
11.3.1 Overview
11.3.2 Business segments
11.3.3 Product portfolio
11.3.4 Financial performance
11.3.5 Recent developments
11.3.6 SWOT analysis
11.4 Aspect Biosystems Ltd.
11.4.1 Overview
11.4.2 Business segments
11.4.3 Product portfolio
11.4.4 Financial performance
11.4.5 Recent developments
11.4.6 SWOT analysis
11.5 EnvisionTEC GmbH
11.5.1 Overview
11.5.2 Business segments
11.5.3 Product portfolio
11.5.4 Financial performance
11.5.5 Recent developments
11.5.6 SWOT analysis
11.6 Cyfuse Biomedical K.K.
11.6.1 Overview
11.6.2 Business segments
11.6.3 Product portfolio
11.6.4 Financial performance
11.6.5 Recent developments
11.6.6 SWOT analysis
11.7 Poietis
11.7.1 Overview
11.7.2 Business segments
11.7.3 Product portfolio
11.7.4 Financial performance
11.7.5 Recent developments
11.7.6 SWOT analysis
11.8 TeVido BioDevices
11.8.1 Overview
11.8.2 Business segments
11.8.3 Product portfolio
11.8.4 Financial performance
11.8.5 Recent developments
11.8.6 SWOT analysis
11.9 Nano3D Biosciences, Inc.
11.9.1 Overview
11.9.2 Business segments
11.9.3 Product portfolio
11.9.4 Financial performance
11.9.5 Recent developments
11.9.6 SWOT analysis
11.10 ROKIT Healthcare
11.10.1 Overview
11.10.2 Business segments
11.10.3 Product portfolio
11.10.4 Financial performance
11.10.5 Recent developments
11.10.6 SWOT analysis
11.11 Digilab, Inc.
11.11.1 Overview
11.11.2 Business segments
11.11.3 Product portfolio
11.11.4 Financial performance
11.11.5 Recent developments
11.11.6 SWOT analysis
11.12
11.12.1 Overview
11.12.2 Business segments
11.12.3 Product portfolio
11.12.4 Financial performance
11.12.5 Recent developments
11.12.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
